Jecure Therapeutics is focused on the discovery of innovative therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) and liver fibrosis. Jecure combines emerging NASH biology with an elite discovery team of veteran pharma and biotech scientists.Learn More About Jecure
- Feb 28, 2018Jecure Therapeutics to Present at the 2018 EASL Meeting on Their Lead NLRP3 Inflammasome Assembly Blocker (NAB) Program.
- Jan 2, 2018Jecure Therapeutics Featured in Biospace's Top 20 Life Science Startups to Watch in 2018
Contact JecureJecure Therapeutics
4757 Nexus Center Drive, Suite 150
San Diego, CA 92121
(619) 541-8699 Email: